Introduction
Upper gastrointestinal hemorrhage (UGH) is a serious medical condition with an annual incidence of 89.8 per 100,000 populations. Males between 61 and 69 are more likely to suffer from this disease compared with other individuals and the overall mortality of UGH is about 8.2 cases per 100,000 populations per year [1] . For non-variceal UGH, the use of non-steroidal anti-inflammatory drugs (NSAIDs) and H. pylori infections are two common risk factors for upper gastrointestinal bleeding [2] . The development of endoscopic therapy reduces the incidence of rebleeding, need for surgery and the modality of UGH significantly. Endoscopic therapy is usually carried out in conjunction with proton pump inhibitors (PPIs), histamine H 2 receptor antagonist (H2RA), somatostatin analogues and tranexamic acid. It is challenging for clinicians to determine the appropriate medication that should be accompanied with endoscopic therapy and thereby we designed this study to address this issue.
PPIs such as omeprazole, pantoprazole, tenatoprazole and lansoprazole have been widely used to treat peptic ulcer diseases and they are effective in managing bleeding resulted from endoscopic therapy. PPIs were developed in the 1980s [3] and they irreversibly block the H + /K + ATPase which is known as the gastric proton pump of the gastric parietal cells [4] . PPIs are able to impede the terminal stage of gastric acid secretion and thereby healing duodenal ulcers and alleviating pain due to indigestion or heartburn. H2RAs including cimetidine, ranitidine, famotidine and nizatidine are another type of antagonists which target the H 2 receptor of parietal cells. Histamine excreted by ECL cells contained in the stomach can bind to H 2 receptors on parietal cells and thereby stimulating acid secretion [5] . As a result, the corresponding acid secretion is inhibited once H2RA is administered to UGH patients.
Somatostatin, also known as the growth hormone-inhibiting hormone, is an inhibitory hormone. The secretion of somatostatin in stomach is induced by low pH conditions. However, the effectiveness of somatostatin analogues is constrained under high pH conditions [6] . Apart from that, somatostatin is able to reduce the portal flow and hence it is usually used in emergency for managing bleeding oesophageal varices in patients with liver cirrhosis [7] . Besides that, somatostatin may suppress pepsin secretion and hence alleviate upper gastrointestinal bleeding. On the other hand, tranexamic acid is a medication which is specifically designed for preventing excessive blood loss due to trauma or surgery [8] . The corresponding mechanism of tranexamic acid is analogous to that of the amino acid lysine. Tranexamic acid is able to bind with receptors on both plasminogen and plasmin and it can act as an antifibrinolytic factor. As suggested by other studies, tranexamic acid is potentially effective for managing gastrointestinal hemorrhage [9] .
Although studies have been conducted to evaluate different types of medications that are used accompanied with endoscopic therapy, comparing several medications simultaneously is rarely found in the current literature. Therefore, our study is set to compare the efficacy and safety of these medications by using the approach of net-work meta-analysis. ). We also reviewed the corresponding reference list of each retrieved articles in order to identify any relevant studies that may be neglected. Retrieved articles were qualified and screened by two independent reviewers (M. Jiang and P. Chen). The corresponding procedures with respect to systematic review are complied with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guideline [10] . Randomized controlled trials (RCTs) were enrolled for further selection if they assessed the performance of PPI, H2RA, somatostatin analogues or tranexamic acid with respect to upper digestive tract hemorrhage.
Material and Methods

Search strategy
Selection criteria
In the current meta-analysis, studies were included if they were in accordance with the following criteria: 1) trials with randomized control trials; 2) all subjects were above the age of 18; 3) the diagnosis of upper gastrointestinal bleeding was confirmed by endoscope; 4) treatments were clearly defined including the type of medication, route of administration and doses; 5) studies included at least one of the following endpoints: rebleeding, all-cause mortality, need for surgery, hospital stay, blood transfusion amounts.
Data extraction
Relevant data from enrolled articles were extracted by two researchers (Mengyuan Jiang and Qiang Gao) independently. Name of the first author, year of publication, study design, sample size, duration of the follow-up period, mean age of enrolled subjects, gender of subjects, the corresponding percentage of duodenal ulcer and gastric ulcer in the sample, NSAID status, H. pylori infection status, medication details and clinical outcomes were documented for data analysis. Various clinical outcomes including rebreeding, all-cause mortality, need for surgery, hospital stay and blood transfusion amount were compared among different medications by using the net-work meta-analysis. Disagreement with respect to data extraction was resolved by a third reviewer (Qiang Gao).
Statistical analysis
In the present study, direct evidence from conventional meta-analysis was reinforced by net-work meta-analysis which synthesized indirect evidence within a net-work enclosed by various medications. The odds ratio (OR) and their corresponding 95%CI were used to compare different medications with respect to various clinical outcomes. Conventional meta-analysis compared one medication to the placebo and this process was iterated for each medication whereas net-work meta-analysis compared several medications simultaneously within the net-work. Heterogeneity among studies was assessed by using the Cochran's Q-statistic and I 2 test. Significant heterogeneity was concluded if the corresponding P-value of the Cochran's Q test is less than 0.01 or I 2 > 50%. The fixed-effect model (Mantel-Haenszel method) was applied within the analysis if no significant heterogeneity was concluded whereas the random-effects model (DerSimonian-Laird method) was implemented in the case of significant heterogeneity. All statistical procedures were carried out by using STATA version 12.0 (StataCorp, College Station, TX, USA) software.
In contrary to the conventional meta-analysis, a random-effects model within a Bayesian framework using Markov chain Monte Carlo methods was implemented for the net-work meta-analysis and the corresponding procedures were carried out by using WinBUGS (MRC Bio-statistics Unit, Cambridge, UK). Medications were compared using the statistics of ORs and their 95%CrIs. The ranking probabilities with respect to each clinical outcome were also obtained by using the surface under the cumulative ranking curve (SUCRA) [11] . Besides that, the overall ORs and their corresponding interval were compared between the conventional meta-analysis and net-work meta-analysis in order to assess consistency between direct and indirect evidence.
Results
Study characteristics
A total of 47 articles were enrolled in this meta-analysis [7, . We subsequently divided the interventions into the following nine groups on the basis of medication type, administration route and dose: placebo/no treatment, H2RA, high-dose i.v. PPI, i.v. PPI, i.v. PPI+H2RA, p.o. PPI, p.o. PPI + tranexamic acid, tranexamic acid and somatostatin analogues.
The following clinical outcomes we studied in this analysis: rebleeding, all-cause mortality, need for surgery, hospital stay and blood transfusion amount. In all, 9,528 subjects with UGH were enrolled in our analysis. Main characteristics of selected studies were summarized in Table 1 . Besides, a net-work plot of relevant studies was illustrated in Fig. 1 which depicts the corresponding comparisons within the net-work.
Rebleeding
Comparisons among medications with respect to the event of rebleeding are illustrated in Table 2 
All-cause mortality
Comparisons among medications with respect to all-cause mortality are presented in Table 3 and Fig. 3 . No significant difference in the risk of all-cause mortality was identified Table 5 and Fig. 5 illustrate the corresponding comparisons of hospital stay duration for UGH patients managed by different medications. Patients treated with H2RA or PPI (p.o.) exhibit a decrease in the average hospital stay duration compared to those treated by 
Hospital stay
Blood transfusion amount
Likewise, comparisons among medications with respect to the blood transfusion amount are displayed in Table 6 
Ranking of seven medications
Net-work meta-analysis also provides a comprehensive ranking by using the corresponding SUCRA values. A larger SUCRA value indicates that one medication is superior to others and hence it will have a relatively high ranking ( Table 7) . As suggested by the SUCRA values, PPI (i.v.) and PPI (p.o.) appear to have strength in reducing the risk of all-cause mortality, average hospital stay and average blood transfusion amount. On the other hand, tranexamic acid is particularly effective for reducing the risk of rebleeding and it exhibit reliable performance with respect to all-cause mortality and need for surgery. By contrast, H2RA appears to have a relatively low ranking with respect to all of the five clinical outcomes. 
Discussion
In our study, we performed both traditional pair-wise and net-work meta-analysis to evaluate the effectiveness of H2RA, PPI, somatostatin analogue and tranexamic acid for patients with UGH. According to the results, PPI (i.v.) and PPI (p.o.) exhibit great therapeutic performance since they not only effectively reduce the risk of rebleeding, all-cause mortality and need for surgery but also reduce the average hospital stay as well as the average blood transfusion amount. Tranexamic acid also ranks high with respect to rebleeding, all-cause mortality and need for surgery. H2RA exhibits a low rank with respect to these clinical outcomes and therefore its tolerability should be further verified.
This is a large-scale study which simultaneously evaluates the tolerability of various UGH medications. Our results exhibit strong consistency with those suggested by Zhang et al. who concluded that PPI is more effective than H2RA for UGH patients [58] . Another study indicates that high-dose PPI is as effective as low-dose PPI with respect to the risk of rebleeding, need for surgery and mortality [59, 60] . As suggested by previous studies, the effectiveness and tolerability of PPI is not significantly affected by its administration routes. However, our results suggest that oral administration of PPI appears to be more tolerable than intravenous PPI since the corresponding risk of adverse effects is reduced [61] .
H2RA is a medication which is usually recommended for managing bleeding gastric ulcer and its effectiveness in bleeding duodenal ulcer is still uncertain [62] . Furthermore, bleeding location appears to have influence on the effectiveness of H2RA but evidence with respect to this issue is very limited. The effect of tranexamic acid on upper gastrointestinal bleeding has also been mentioned [63] , while further studies were still recommended to assess the effectiveness and tolerability of tranexamic acid.
The net-work meta-analysis enables us to combine both direct and indirect evidences so that various medications can be evaluated simultaneously. Results from traditional metaanalysis and net-work meta-analysis were in contradiction in some cases. Although the inclusion of indirect evidence significantly increased our sample size, the corresponding heterogeneity and bias might also be enlarged. Apart from that, we assume that patients with no treatments have the same effect as those who were treated by placebo and such an assumption should be validated. Moreover, the blood transfusion amount was reported in different units and we converted different units of blood transfusion amount into a common standard so that results can be comparable. Also, we did not perform any stratified analysis with respect to dose and administration route which are likely to be associated with the corresponding clinical outcomes. Finally, bleeding location of each patient was not considered in our study and this issue should be addressed by further studies.
Overall, PPI is an effective medication for UGH. Both intravenous and oral administration of PPI may provide equivalent tolerability for UGH patients. However, high dose PPI is associated with an increase in the risk of all cause death and need for surgery compared to low dose PPI. On the other hand, H2RA is not recommended for UGH patients since they do not provide effective solution for rebleeding, need for surgery and all-cause mortality. Tranexamic acid is also considered as a promising for UGH patients. Nevertheless, we encourage researchers and clinicians to work together for confirming the above conclusions since determining the appropriate medication for UGH patients is not simply a question to be solved by trial-and-error.
